4.6 Review

Adiponectin, the past two decades

Journal

JOURNAL OF MOLECULAR CELL BIOLOGY
Volume 8, Issue 2, Pages 93-100

Publisher

OXFORD UNIV PRESS
DOI: 10.1093/jmcb/mjw011

Keywords

adiponectin; diabetes; obesity; metabolic syndrome

Categories

Funding

  1. American Heart Association [14SDG18440002]
  2. National Institutes of Health [R01-DK55758, R01-DK099110, P01-DK088761]

Ask authors/readers for more resources

Adiponectin is an adipocyte-specific factor, first described in 1995. Over the past two decades, numerous studies have elucidated the physiological functions of adiponectin in obesity, diabetes, inflammation, atherosclerosis, and cardiovascular disease. Adiponectin, elicited through cognate receptors, suppresses glucose production in the liver and enhances fatty acid oxidation in skeletal muscle, which together contribute to a beneficial metabolic action in whole body energy homeostasis. Beyond its role in metabolism, adiponectin also protects cells from apoptosis and reduces inflammation in various cell types via receptor-dependent mechanisms. Adiponectin, as a fat-derived hormone, therefore fulfills a critical role as an important messenger to communicate between adipose tissue and other organs. A better understanding of adiponectin actions, including the pros and cons, will advance our insights into basic mechanisms of metabolism and inflammation, and potentially pave the way toward novel means of pharmacological intervention to address pathophysiological changes associated with diabetes, atherosclerosis, and cardiometabolic disease.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available